Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

摘要: Background Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to tyrosine kinase inhibitors gefitinib and erlotinib patients with advanced non–small-cell lung cancer. We evaluated feasibility of large-scale screening for EGFR such analyzed association between outcome treatment. Methods From April 2005 through November 2008, cancers from 2105 129 institutions Spain were screened mutations. The analysis was performed a central laboratory. Patients tumors carrying eligible Results found 350 (16.6%). Mutations more frequent women (69.7%), who had never smoked (66.6%), those adenocarcinomas (80.9%) (P<0.001 all comparisons). deletions exon 19 (62.2%) L858R (37.8%). Median progression-free survival overall ...